Uricases as therapeutic agents to treat refractory gout: Current states and future directions

Drug Development Research

Volumn 73, Issue 2, 2012, Pages 66-72

  Yang, Xiaolan ^a   Yuan, Yonghua ^a   Zhan, Chang Guo ^b   Liao, Fei ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b University of Kentucky   (United States)

Author keywords

hyperuricemia; molecular engineering; refractory gout; uricase

Indexed keywords

ADENOSINE DEAMINASE; ALLOPURINOL; AMINO ACID; ASPARAGINASE MACROGOL; FEBUXOSTAT; PEGINTERFERON ALPHA; PEGLOTICASE; PROBENECID; RABURICASE; UNCLASSIFIED DRUG; URATE OXIDASE; XANTHINE;

DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; GOUT; HEPATITIS C; HYPERURICEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; REVIEW;

EID: 84859890297     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20493     Document Type: Review

References (65)

1. Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK, Little AS,. 1970. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 283: 354-357.
2. Bessmertny O, Robitaille LM, Cairo MS,. 2005. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr Pharm Des 11: 4177-4185. (Pubitemid 41672466)
3. Bryson CJ, Jones TD, Baker MP,. 2010. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 24: 1-8.
4. Chen CY, Georgiev I, Anderson AC, Donald BR,. 2009. Computational structure-based redesign of enzyme activity. Proc Natl Acad Sci U S A 106: 3764-3769.
5. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR,. 2000. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 11: 258-266. (Pubitemid 30174492)
6. Chica RA, Doucet N, Pelletier JN,. 2005. Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design. Curr Opin Biotechnol 16: 378-384. (Pubitemid 41111523)
7. Chohan S, Becker MA,. 2009. Update on emerging urate-lowering therapies. Curr Opin Rheumatol 21: 143-149.
8. Danhof M, de, Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA,. 2007. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47: 357-400.
9. Danhof M, de, Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA,. 2008. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29: 186-191.
10. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ,. 2004. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116: 546-554. (Pubitemid 38452647)
11. Edwards NL,. 2008. Treatment-failure gout: a moving target. Arthritis Rheum 58: 2587-2590.
12. Feig DI,. 2009. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 18: 526-530.
13. Feig DI, Kang DH, Johnson RJ,. 2008. Uric acid and cardiovascular risk. N Engl J Med 359: 1811-1821.
14. Fels E, Sundy JS,. 2008. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol 20: 198-202. (Pubitemid 351339893)
15. Feng J, Li X, Yang XL, Zhang C, Yuan YH, Pu J, Zhao YS, Xie YL, Yuan HD, Bu YQ, et al. 2010. A new practical system for evaluating pharmacological properties of uricase as potential drug to handle hyperuricemia. Arch Pharm Res 33: 1761-1769.
16. Foster GR,. 2010. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 70: 147-165.
17. Fridovich I,. 1965. The competitive inhibition of uricase by oxonate and by related derivatives of S-triazines. J Biol Chem 240: 2491-2494.
18. Gaberc-Porekar V, Zore I, Podobnik B, Menart V,. 2008. Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr Opin Drug Discov Devel 11: 242-250. (Pubitemid 351281064)
19. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS,. 2006. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8: R12.
20. Gao D, Cho H, Yang W, Pan Y, Yang G, Tai HH, Zhan CG,. 2006. Computational design of a human butyrylcholinesterase mutant for accelerating cocaine hydrolysis based on the transition-state simulation. Angew Chem Int Ed Engl 45: 653-657. (Pubitemid 43121468)
21. Gao D, Narasimhan DL, Macdonald J, Brim R, Ko MC, Landry DW, Woods JH, Sunahara RK, Zhan CG,. 2009. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol 75: 318-323.
22. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD,. 2009. How I treat ADA deficiency. Blood 114: 3524-3532.
23. Haag R, Kratz F,. 2006. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 45: 1198-1215. (Pubitemid 44097641)
24. Hande KR, Perini F, Putterman G, Elin R,. 1979. Hyperxanthinemia interferes with serum uric acid determinations by the uricase method. Clin Chem 25: 1492-1494. (Pubitemid 9247046)
25. Ishida T, Kiwada H,. 2008. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354: 56-62.
26. Ishida T, Atobe K, Wang X, Kiwada H,. 2006. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection. J Control Release 115: 251-258. (Pubitemid 44634849)
27. Kahn K, Tipton PA,. 1998. Spectroscopic characterization of intermediates in the urate oxidase reaction. Biochemistry 37: 11651-11659. (Pubitemid 28388209)
28. Kang DH, Nakagawa T,. 2005. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 25: 43-49. (Pubitemid 40128148)
29. Keenan RT, Pillinger MH,. 2009. Febuxostat: a new agent for lowering serum urate. Drugs Today 45: 247-260.
30. Kelly SJ, Delnomdedieu M, Oliverio MI, Williams LD, Saifer MG, Sherman MR, Coffman TM, Johnson GA, Hershfield MS,. 2001. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 12: 1001-1009. (Pubitemid 32378341)
31. Kumarasiri M, Baker GA, Soudackov AV, Hammes-Schiffer S,. 2009. Computational approach for ranking mutant enzymes according to catalytic reaction rates. J Phys Chem B 113: 3579-3583.
32. Labrou NE,. 2010. Random mutagenesis methods for in vitro directed enzyme evolution. Curr Protein Pept Sci 11: 91-100.
33. Liao F, Liu WL, Zhou QX, Zeng ZC, Zuo YP,. 2001. Assay of serum arylesterase activity by fitting to the reaction curve with an integrated rate equation. Clin Chim Acta 314: 67-76. (Pubitemid 33079185)
34. Liao F, Zhu XY, Wang YM, Zuo YP,. 2005. The comparison of the estimation of enzyme kinetic parameters by fitting reaction curve to the integrated Michaelis-Menten rate equations of different predictor variables. J Biochem Biophys Methods 62: 13-24. (Pubitemid 40138073)
35. Liu Z, Lu D, Li J, Chen W, Liu Z,. 2009. Strengthening intersubunit hydrogen bonds for enhanced stability of recombinant urate oxidase from Aspergillus flavus: molecular simulations and experimental validation. Phys Chem Chem Phys 11: 333-340.
36. Lonsdale R, Ranaghan KE, Mulholland AJ,. 2010. Computational enzymology. Chem Commun 46: 2354-2372.
37. Marsac Y, Cramer J, Olschewski D, Alexandrov K, Becker CF,. 2006. Site-specific attachment of polyethylene glycol-like oligomers to proteins and peptides. Bioconjug Chem 17: 1492-1498. (Pubitemid 44851494)
38. Mughal TI, Ejaz AA, Foringer JR, Coiffier B,. 2010. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 36: 164-176.
39. Pan Y, Gao D, Yang W, Cho H, Yang G, Tai HH, Zhan CG,. 2005. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci U S A 102: 16656-16661. (Pubitemid 41688832)
40. Pan Y, Gao D, Yang W, Cho H, Zhan CG,. 2007. Free energy perturbation (FEP) simulation on the transition states of cocaine hydrolysis catalyzed by human butyrylcholinesterase and its mutants. J Am Chem Soc 129: 13537-13543. (Pubitemid 350071782)
41. Pan Y, Gao D, Zhan CG,. 2008. Modeling the catalysis of anti-cocaine catalytic antibody: competing reaction pathways and free energy barriers. J Am Chem Soc 130: 5140-5149. (Pubitemid 351537074)
42. Pasut G, Sergi M, Veronese FM,. 2008. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 60: 69-78. (Pubitemid 350181167)
43. Petrounia IP, Arnold FH,. 2000. Designed evolution of enzymatic properties. Curr Opin Biotechnol 11: 325-330. (Pubitemid 30598925)
44. Ramazzina I, Folli C, Secchi A, Berni R, Percudani R,. 2006. Completing the uric acid degradation pathway through phylogenetic comparison of whole genomes. Nat Chem Biol 2: 144-148. (Pubitemid 44323865)
45. Richette P, Bardin T,. 2006. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol 2: 338-342. (Pubitemid 43852765)
46. Richette P, Bardin T,. 2010. Gout. Lancet 375: 318-328.
47. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P,. 2009. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 360: 257-267.
48. Sarkissian CN, Gamez A, Wang L, Charbonneau M, Fitzpatrick P, Lemontt JF, Zhao B, Vellard M, Bell SM, Henschell C, et al. 2008. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci U S A 105: 20894-20899.
49. Sato H,. 2002. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 54: 487-504. (Pubitemid 34615545)
50. Schlesinger N, Yasothan U, Kirkpatrick P,. 2011. Pegloticase. Nat Rev Drug Discov 10: 17-18.
51. Sestigiani E, Mandreoli M, Guardigli M, Roda A, Ramazzotti E, Boni P, Santoro A,. 2008. Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease. Nephron Clin Pract 108: c265-c271. (Pubitemid 351720808)
52. Sherman MR, Saifer MG, Perez-Ruiz F,. 2008. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 60: 59-68. (Pubitemid 350186186)
53. Su YC, Chen BM, Chuang KH, Cheng TL, Roffler SR,. 2010. Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies. Bioconjug Chem 21: 1264-1270.
54. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS,. 2007. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum 56: 1021-1028. (Pubitemid 46399452)
55. Terkeltaub R,. 2010. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 6: 30-38.
56. Tsuji J, Hirose K, Kasahara E, Naitoh M, Yamamoto I,. 1985. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase. Int J Immunopharmacol 7: 725-730. (Pubitemid 16255837)
57. Vogt B,. 2005. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant 20: 431-433. (Pubitemid 40276903)
58. Voigt CA, Kauffman S, Wang ZG,. 2000. Rational evolutionary design: the theory of in vitro protein evolution. Adv Protein Chem 55: 79-160.
59. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C Jr., Jones P, Bradley A, Caskey CT,. 1994. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 91: 742-746. (Pubitemid 24041478)
60. Yang W, Pan Y, Zheng F, Cho H, Tai HH, Zhan CG,. 2009. Free-energy perturbation simulation on transition states and redesign of butyrylcholinesterase. Biophys J 96: 1931-1938.
61. Yue CS, Huang W, Alton M, Maroli AN, Waltrip RW, Wright D, Marco MD,. 2008. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout. J Clin Pharmacol 48: 708-718. (Pubitemid 351713156)
62. Zhang C, Yang X, Feng J, Yuan Y, Li X, Bu Y, Xie Y, Yuan H, Liao F,. 2010. Effects of modification of amino groups with poly(ethylene glycol) on a recombinant uricase from Bacillus fastidiosus. Biosci Biotechnol Biochem 74: 1298-1301.
63. Zhao Y, Yang X, Li X, Bu Y, Deng P, Zhang C, Feng J, Xie Y, Zhu S, Yuan H, et al. 2009. Reversible inactivation of an intracellular uricase from Bacillus fastidiosus via dissociation of homotetramer into homodimers in solutions of low ionic strength. Biosci Biotechnol Biochem 73: 2141-2144.
64. Zhao Y, Zhao L, Yang G, Tao J, Bu Y, Liao F,. 2006. Characterization of a uricase from Bacillus fastidious A.T.C.C. 26904 and its application to serum uric acid assay by a patented kinetic uricase method. Biotechnol Appl Biochem 45: 75-80. (Pubitemid 44358592)
65. Zheng F, Yang W, Ko M-C, Liu J, Cho H, Gao D, Tong M, Tai H-H, Woods JH, Zhan CG,. 2008. Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc 130: 12148-12155.